{"title":"Neurotrophin-3 gene polymorphism in schizophrenia and its relation with diseases severity and cognitive dysfunction.","authors":"Neha Keshri, Hanumanthappa Nandeesha, Medha Rajappa, Vikas Menon","doi":"10.25259/JNRP_34_2022","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Synaptic plasticity markers are known to alter in schizophrenia. The objective of the study was to investigate the genotype and allele frequency of neurotrophin-3 (NT-3) gene polymorphism (rs6489630, rs6332, and rs11063714) and plasma NT-3 levels in schizophrenia and their relation with cognitive status.</p><p><strong>Materials and methods: </strong>The study was conducted on 216 Schizophrenia patients and 216 controls. Single-nucleotide polymorphism (SNP) of NT-3 and its plasma levels were assessed in both groups. Cognitive status was evaluated using Addenbrooke Cognitive examination-III scores.</p><p><strong>Results: </strong>The rs6489630 polymorphism was found to be significantly associated with the severity of schizophrenia (<i>P</i> = 0.004). The CT genotype (<i>P</i> = 0.02, OR = 1.631 [1.10-2.43]) and minor allele T (<i>P</i> = 0.004, OR = 1.58 [1.16-2.16]) of rs6489630 conferred an increased susceptibility to develop schizophrenia. The rs6332 variant was found to affect cognitive status significantly in schizophrenia (<i>P</i> = 0.040), and memory dysfunction was seen in individuals with AG (<i>P</i> < 0.01) and AA variant (<i>P</i> = 0.03) of rs6332.</p><p><strong>Conclusion: </strong>We conclude that SNPs of NT-3 enhance the risk of schizophrenia and are related to cognitive dysfunction.</p>","PeriodicalId":16443,"journal":{"name":"Journal of Neurosciences in Rural Practice","volume":"14 3","pages":"501-508"},"PeriodicalIF":0.8000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483217/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurosciences in Rural Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/JNRP_34_2022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Synaptic plasticity markers are known to alter in schizophrenia. The objective of the study was to investigate the genotype and allele frequency of neurotrophin-3 (NT-3) gene polymorphism (rs6489630, rs6332, and rs11063714) and plasma NT-3 levels in schizophrenia and their relation with cognitive status.
Materials and methods: The study was conducted on 216 Schizophrenia patients and 216 controls. Single-nucleotide polymorphism (SNP) of NT-3 and its plasma levels were assessed in both groups. Cognitive status was evaluated using Addenbrooke Cognitive examination-III scores.
Results: The rs6489630 polymorphism was found to be significantly associated with the severity of schizophrenia (P = 0.004). The CT genotype (P = 0.02, OR = 1.631 [1.10-2.43]) and minor allele T (P = 0.004, OR = 1.58 [1.16-2.16]) of rs6489630 conferred an increased susceptibility to develop schizophrenia. The rs6332 variant was found to affect cognitive status significantly in schizophrenia (P = 0.040), and memory dysfunction was seen in individuals with AG (P < 0.01) and AA variant (P = 0.03) of rs6332.
Conclusion: We conclude that SNPs of NT-3 enhance the risk of schizophrenia and are related to cognitive dysfunction.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
